Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Choreo LLC

Choreo LLC boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.0% in the 4th quarter, Holdings Channel reports. The firm owned 15,235 shares of the medical equipment provider’s stock after buying an additional 729 shares during the quarter. Choreo LLC’s holdings in Zimmer Biomet were worth $1,607,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Tectonic Advisors LLC increased its holdings in Zimmer Biomet by 21.7% in the 4th quarter. Tectonic Advisors LLC now owns 4,439 shares of the medical equipment provider’s stock valued at $469,000 after purchasing an additional 792 shares in the last quarter. Money Concepts Capital Corp increased its holdings in Zimmer Biomet by 5.9% in the 4th quarter. Money Concepts Capital Corp now owns 3,538 shares of the medical equipment provider’s stock valued at $374,000 after purchasing an additional 196 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Zimmer Biomet by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,156 shares of the medical equipment provider’s stock valued at $2,361,000 after purchasing an additional 4,645 shares in the last quarter. E. Ohman J or Asset Management AB increased its holdings in Zimmer Biomet by 14.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 10,150 shares of the medical equipment provider’s stock valued at $1,072,000 after purchasing an additional 1,250 shares in the last quarter. Finally, Mather Group LLC. increased its holdings in Zimmer Biomet by 100.9% in the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock valued at $70,000 after purchasing an additional 332 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ZBH. Raymond James lowered their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday. Wells Fargo & Company upped their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Barclays decreased their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research report on Thursday, December 12th. Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Finally, Oppenheimer decreased their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $124.70.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $101.01 on Friday. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The firm’s 50-day moving average price is $107.56 and its two-hundred day moving average price is $108.16. Zimmer Biomet Holdings, Inc. has a 52-week low of $99.93 and a 52-week high of $133.90. The stock has a market capitalization of $20.11 billion, a P/E ratio of 19.20, a P/E/G ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. During the same period in the previous year, the company earned $2.20 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.95%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.